Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib

Alicia Bort, Belén G. Sánchez, Pedro A. Mateos-Gómez, Diana Vara-Ciruelos, Nieves Rodríguez-Henche, Inés Díaz-Laviada (Lead / Corresponding author)

Research output: Contribution to journalArticle

33 Downloads (Pure)

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. HCC treatment is hindered by the frequent emergence of chemoresistance to the multikinase inhibitor sorafenib, which has been related to the presence of cancer stem cells (CSCs) that self-renew and often escape therapy. The key metabolic sensor AMP-activated kinase (AMPK) has recently been recognized as a tumour growth regulator. In this study, we aimed to elucidate the role of AMPK in the development of a stem cell phenotype in HCC cells. To this end, we enriched the CSC population in HCC cell lines that showed increased expression of drug resistance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha fetoprotein) markers and demonstrated their stemness phenotype. These cells were refractory to sorafenib-induced cell death. We report that sorafenib-resistant cells had lower levels of total and phosphorylated AMPK as well as its downstream substrate, ACC, compared with the parental cells. Interestingly, AMPK knockdown with siRNA or inhibition with dorsomorphin increased the expression of stem cell markers in parental cells and blocked sorafenib-induced cell death. Conversely, the upregulation of AMPK, either by transfection or by pharmacological activation with A-769662, decreased the expression of ALDH1A1, ABCB1A, CD133, Nanog, Oct4, and alpha fetoprotein, and restored sensitivity to sorafenib. Analysis of the underlying mechanism points to hypoxia-inducible factor HIF-1α as a regulator of stemness. In vivo studies in a xenograft mouse model demonstrated that stem-like cells have greater tumourigenic capacity. AMPK activation reduced xenograft tumour growth and decreased the expression of stem cell markers. Taken together, these results indicate that AMPK may serve as a novel target to overcome chemoresistance in HCC.

Original languageEnglish
Pages (from-to)1311-1331
Number of pages21
JournalMolecular Oncology
Volume13
Issue number5
Early online date8 Apr 2019
DOIs
Publication statusPublished - May 2019

Fingerprint

AMP-Activated Protein Kinases
Neoplastic Stem Cells
Liver Neoplasms
Hepatocellular Carcinoma
Stem Cells
alpha-Fetoproteins
Heterografts
A 769662
Cell Death
Phenotype
Hypoxia-Inducible Factor 1
Neoplasms
Growth
sorafenib
Drug Resistance
Small Interfering RNA
Transfection
Cause of Death
Up-Regulation
Pharmacology

Keywords

  • AMP-activated kinase
  • cancer stem cells
  • drug resistance
  • hepatocellular carcinoma
  • sorafenib

Cite this

Bort, Alicia ; Sánchez, Belén G. ; Mateos-Gómez, Pedro A. ; Vara-Ciruelos, Diana ; Rodríguez-Henche, Nieves ; Díaz-Laviada, Inés. / Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib. In: Molecular Oncology. 2019 ; Vol. 13, No. 5. pp. 1311-1331.
@article{cf7142ae856e495895639c444a2142d3,
title = "Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib",
abstract = "Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. HCC treatment is hindered by the frequent emergence of chemoresistance to the multikinase inhibitor sorafenib, which has been related to the presence of cancer stem cells (CSCs) that self-renew and often escape therapy. The key metabolic sensor AMP-activated kinase (AMPK) has recently been recognized as a tumour growth regulator. In this study, we aimed to elucidate the role of AMPK in the development of a stem cell phenotype in HCC cells. To this end, we enriched the CSC population in HCC cell lines that showed increased expression of drug resistance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha fetoprotein) markers and demonstrated their stemness phenotype. These cells were refractory to sorafenib-induced cell death. We report that sorafenib-resistant cells had lower levels of total and phosphorylated AMPK as well as its downstream substrate, ACC, compared with the parental cells. Interestingly, AMPK knockdown with siRNA or inhibition with dorsomorphin increased the expression of stem cell markers in parental cells and blocked sorafenib-induced cell death. Conversely, the upregulation of AMPK, either by transfection or by pharmacological activation with A-769662, decreased the expression of ALDH1A1, ABCB1A, CD133, Nanog, Oct4, and alpha fetoprotein, and restored sensitivity to sorafenib. Analysis of the underlying mechanism points to hypoxia-inducible factor HIF-1α as a regulator of stemness. In vivo studies in a xenograft mouse model demonstrated that stem-like cells have greater tumourigenic capacity. AMPK activation reduced xenograft tumour growth and decreased the expression of stem cell markers. Taken together, these results indicate that AMPK may serve as a novel target to overcome chemoresistance in HCC.",
keywords = "AMP-activated kinase, cancer stem cells, drug resistance, hepatocellular carcinoma, sorafenib",
author = "Alicia Bort and S{\'a}nchez, {Bel{\'e}n G.} and Mateos-G{\'o}mez, {Pedro A.} and Diana Vara-Ciruelos and Nieves Rodr{\'i}guez-Henche and In{\'e}s D{\'i}az-Laviada",
note = "This work was supported by the Tatiana P{\'e}rez de Guzm{\'a}n Foundation [grant number Patrocinio 2013‐01]. BSG is a fellowship from the Spanish Education, Culture and Sports Ministry.",
year = "2019",
month = "5",
doi = "10.1002/1878-0261.12488",
language = "English",
volume = "13",
pages = "1311--1331",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "5",

}

Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib. / Bort, Alicia; Sánchez, Belén G.; Mateos-Gómez, Pedro A.; Vara-Ciruelos, Diana; Rodríguez-Henche, Nieves; Díaz-Laviada, Inés (Lead / Corresponding author).

In: Molecular Oncology, Vol. 13, No. 5, 05.2019, p. 1311-1331.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeting AMP-activated kinase impacts hepatocellular cancer stem cells induced by long-term treatment with sorafenib

AU - Bort, Alicia

AU - Sánchez, Belén G.

AU - Mateos-Gómez, Pedro A.

AU - Vara-Ciruelos, Diana

AU - Rodríguez-Henche, Nieves

AU - Díaz-Laviada, Inés

N1 - This work was supported by the Tatiana Pérez de Guzmán Foundation [grant number Patrocinio 2013‐01]. BSG is a fellowship from the Spanish Education, Culture and Sports Ministry.

PY - 2019/5

Y1 - 2019/5

N2 - Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. HCC treatment is hindered by the frequent emergence of chemoresistance to the multikinase inhibitor sorafenib, which has been related to the presence of cancer stem cells (CSCs) that self-renew and often escape therapy. The key metabolic sensor AMP-activated kinase (AMPK) has recently been recognized as a tumour growth regulator. In this study, we aimed to elucidate the role of AMPK in the development of a stem cell phenotype in HCC cells. To this end, we enriched the CSC population in HCC cell lines that showed increased expression of drug resistance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha fetoprotein) markers and demonstrated their stemness phenotype. These cells were refractory to sorafenib-induced cell death. We report that sorafenib-resistant cells had lower levels of total and phosphorylated AMPK as well as its downstream substrate, ACC, compared with the parental cells. Interestingly, AMPK knockdown with siRNA or inhibition with dorsomorphin increased the expression of stem cell markers in parental cells and blocked sorafenib-induced cell death. Conversely, the upregulation of AMPK, either by transfection or by pharmacological activation with A-769662, decreased the expression of ALDH1A1, ABCB1A, CD133, Nanog, Oct4, and alpha fetoprotein, and restored sensitivity to sorafenib. Analysis of the underlying mechanism points to hypoxia-inducible factor HIF-1α as a regulator of stemness. In vivo studies in a xenograft mouse model demonstrated that stem-like cells have greater tumourigenic capacity. AMPK activation reduced xenograft tumour growth and decreased the expression of stem cell markers. Taken together, these results indicate that AMPK may serve as a novel target to overcome chemoresistance in HCC.

AB - Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide. HCC treatment is hindered by the frequent emergence of chemoresistance to the multikinase inhibitor sorafenib, which has been related to the presence of cancer stem cells (CSCs) that self-renew and often escape therapy. The key metabolic sensor AMP-activated kinase (AMPK) has recently been recognized as a tumour growth regulator. In this study, we aimed to elucidate the role of AMPK in the development of a stem cell phenotype in HCC cells. To this end, we enriched the CSC population in HCC cell lines that showed increased expression of drug resistance (ALDH1A1, ABCB1A) and stem cell (CD133, Nanog, Oct4, alpha fetoprotein) markers and demonstrated their stemness phenotype. These cells were refractory to sorafenib-induced cell death. We report that sorafenib-resistant cells had lower levels of total and phosphorylated AMPK as well as its downstream substrate, ACC, compared with the parental cells. Interestingly, AMPK knockdown with siRNA or inhibition with dorsomorphin increased the expression of stem cell markers in parental cells and blocked sorafenib-induced cell death. Conversely, the upregulation of AMPK, either by transfection or by pharmacological activation with A-769662, decreased the expression of ALDH1A1, ABCB1A, CD133, Nanog, Oct4, and alpha fetoprotein, and restored sensitivity to sorafenib. Analysis of the underlying mechanism points to hypoxia-inducible factor HIF-1α as a regulator of stemness. In vivo studies in a xenograft mouse model demonstrated that stem-like cells have greater tumourigenic capacity. AMPK activation reduced xenograft tumour growth and decreased the expression of stem cell markers. Taken together, these results indicate that AMPK may serve as a novel target to overcome chemoresistance in HCC.

KW - AMP-activated kinase

KW - cancer stem cells

KW - drug resistance

KW - hepatocellular carcinoma

KW - sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85065041330&partnerID=8YFLogxK

U2 - 10.1002/1878-0261.12488

DO - 10.1002/1878-0261.12488

M3 - Article

VL - 13

SP - 1311

EP - 1331

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 5

ER -